CS1-CAR T Cells

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
City of Hope Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Tags
CAR T Cell, SLAMF7
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
978
NCT Identifier
NCT03710421

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.